Crossject SA Faces Stagnation: Can €5 M Funding Ignite Needle‑Free Innovation?
Crossject SA’s stalled pipeline and volatile stock raise doubts—investors wonder if a €5 m boost can spark new needle‑free injection breakthroughs.
2 minutes to read
Crossject SA
Crossject’s Needle‑Free Auto‑Injectors: ZENEO & ZEPIZURE Revolutionizing Emergency Care
Crossject’s needle‑free ZENEO auto‑injector delivers life‑saving drugs like epinephrine, naloxone, and midazolam, with new ZEPIZURE for seizures, backed by €5 m funding and active NYSE‑Euronext trading.
2 minutes to read
Crossject SA Advances Needle-Free Injection Technology, Enhancing Patient Safety and Comfort
Crossject SA, a France-based company, is innovating medical injection systems with needle-free, pre-filled devices designed to enhance patient safety, comfort, and compliance.
2 minutes to read
Crossject SA: Pioneering Patient-Centric Injection Systems Amid Financial Uncertainty
Crossject SA, a France-based medical device company, is a beacon of innovation in healthcare, but its financial volatility and strategic partnerships raise concerns about its long-term viability.
3 minutes to read